<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140222016680N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2022-10-08</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>The effect of transcranial direct current stimulation on upper limb motor function in stroke patients</public_title>
      <acronym></acronym>
      <scientific_title>The effect of the combined Transcranial Direct Current Stimulation with Task- Oriented Training on Electroencephalographic Biomarkers and involved upper limb motor function in hemiparesis post stroke</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-10-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>36</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/66101</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Random blocks (permuted block randomization) with four blocks will be used for randomization. According to the sample size of 36, 18 blocks will be generated using the online site (www.sealedenvelope.com). For concealment in the randomization process, a unique code will be used on each envelope with the type of training specified inside. Stratification will be used in order to have the same distribution in terms of the affected side (right or left hemiplegia) in two groups, Blinding description: In this study, َََََََََََََََََAssessor who evaluates the outcome measures of the survey will be blind to the allocation of the two treatment groups. َAditionally the data also will be assessed by a person who is blind to the type of treatment and treatment of groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>unilateral ischemic stroke.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In this group, transcranial Direct Current Stimulation (tDCs) along with Task-Oriented Training are given for three weeks, 5 sessions per week, and each session for 60 minutes (15 sessions in total). Real-tDCs will be delivered by an anode electrode on the affected hemisphere. Real tDCS lasted 20 min at 2 mA, with a 30s ramp up and 30s ramp down. The exercises include 15 task-oriented exercises focusing on active and active-assistive movements to increase the range of motion of the upper limbs, grasping skills, grasping and moving, and releasing objects. Required equipment, tDCs device, and training supplies include a table, chair, ball, stacking checkers, and playing cards. Intervention 2: Control group: In this group, transcranial Direct Current Stimulation (tDCs) along with task-oriented exercises are given for three weeks, 5 sessions per week, and each session for 60 minutes (15 sessions in total). Sham tDCs will be delivered by the anode electrode on the affected hemisphere for 20 minutes. Sham tDCS consists of a 30-s ramp up followed by a 30-s ramp down of the current and between these intervals, the intensity of the current will be zero. The exercises include 15 task-oriented exercises focusing on active and active-assistive movements to increase the range of motion of the upper limbs, grasping skills, grasping and moving, and releasing objects. Required equipment, tDCs device, and training supplies include tables, chairs, balls, backgammon pieces, and playing cards.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is There is no further information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Shohreh Noorizadeh Dehkordi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation Sciences, Madadkaran Street, Shahnazari Street, Madar Square, Mirdamad, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15459-13487</zip>
        <telephone>+98 21 2222 7124</telephone>
        <email>noorizadeh.sh@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Shohreh Noorizadeh Dehkordi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>School of Rehabilitation Sciences, Madadkaran Street, Shahnazari Street, Madar Square, Mirdamad, Tehran, Iran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>15459-13487</zip>
        <telephone>+98 21 2222 7124</telephone>
        <email>noorizadeh.sh@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Having a first unilateral ischemic stroke as confirmed by the MRI or CT-Scan
At least 6 months have passed since the unilateral stroke
Having the ability to walk for at least 10 meter (with or without cane)
Having motor dysfunction in upper limb with a degree of recovery equal or more than 4 according to the recovery stages of Brunnstrom
Having a score equal or above 26 in the "Montreal Cognitive Assessment"</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>80 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Having moderate to severe depression (a score of 19 or higher on the "Beck depression scale")
Received Botox in the previous 6 months (to enter the study, patients must not have received Botox in the past six months)
Having a contracture in the wrist and fingers of the affected side
Having other neurological disorders such as Parkinson, Multiple Sclerosis and etc.
Having a thalamic stroke or central pain syndrome (Dejerine Roussy Syndrome)
Pain in the affected shoulder (having a score of less than 12 based on the Pain Assessment section of the "Fugle-Meyer assessment" of the upper extremity)
Using drugs that affect the central nervous system
Having pace maker or other stimulation or ferromagnetic implants
Having a history of Seizures in the last two years and taking anticonvulsant drugs during one month before the enrollment in the current study
Pregnancy
unwillingness and lack of cooperation to continue the treatment
Having serious and persistent skin complications or sleep and concentration disorders due to stimulation with tDCs
Not completing the treatment period or occurrence of an accident that affects the motor function or brain activity</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>163.9</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Cerebral infarction, unspecified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In this group, transcranial Direct Current Stimulation (tDCs) along with Task-Oriented Training are given for three weeks, 5 sessions per week, and each session for 60 minutes (15 sessions in total). Real-tDCs will be delivered by an anode electrode on the affected hemisphere. Real tDCS lasted 20 min at 2 mA, with a 30s ramp up and 30s ramp down. The exercises include 15 task-oriented exercises focusing on active and active-assistive movements to increase the range of motion of the upper limbs, grasping skills, grasping and moving, and releasing objects. Required equipment, tDCs device, and training supplies include a table, chair, ball, stacking checkers, and playing cards.</i_keyword>
      <i_keyword>Control group: In this group, transcranial Direct Current Stimulation (tDCs) along with task-oriented exercises are given for three weeks, 5 sessions per week, and each session for 60 minutes (15 sessions in total). Sham tDCs will be delivered by the anode electrode on the affected hemisphere for 20 minutes. Sham tDCS consists of a 30-s ramp up followed by a 30-s ramp down of the current and between these intervals, the intensity of the current will be zero. The exercises include 15 task-oriented exercises focusing on active and active-assistive movements to increase the range of motion of the upper limbs, grasping skills, grasping and moving, and releasing objects. Required equipment, tDCs device, and training supplies include tables, chairs, balls, backgammon pieces, and playing cards.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Electroencephalography parameters include "Absolute power" and "Relative power" and "Average frequency" within each frequency subband (delta, theta, alpha, beta and gamma). Timepoint: before treatment, after treatment (15th session), and 3 months later. Method of measurement: EEG recording.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Upper limb motor function ability by the "Wolf Motor Function Test". Timepoint: before treatment, after treatment (15th session), and 3 months later. Method of measurement: "Wolf Motor Function Test".</sec_outcome>
      <sec_outcome>Upper limb motor function by the upper extremity part of the "Fugl-Meyer Assessment". Timepoint: before treatment, after treatment (15th session), and 3 months later. Method of measurement: Upper Extremity part of the "Fugl-Meyer Assessment".</sec_outcome>
      <sec_outcome>Patient's ability to handle objects of different sizes, weights and shapes. Timepoint: before treatment, after treatment (15th session), and 3 months later. Method of measurement: "Action Research Arm Test".</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2022-02-23</approval_date>
        <contact_name>Ethic committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Expressway Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
